



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C07D 307/38		A1	(11) International Publication Number: WO 98/00416
			(43) International Publication Date: 8 January 1998 (08.01.98)
(21) International Application Number: PCT/US97/11466			(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NI, SN, TD, TG).
(22) International Filing Date: 27 June 1997 (27.06.97)			
(30) Priority Data: 60/021,200 3 July 1996 (03.07.96) US 9615867.0 29 July 1996 (29.07.96) GB			
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): DESMOND, Richard [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DOLLING, Ulf, H. [DE/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). FREY, Lisa, F. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). TILLYER, Richard, D. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). TSCHAEN, David, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			


Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: PROCESS OF PREPARING PHENYL HETEROCYCLES USEFUL AS COX-2 INHIBITORS

(57) Abstract

The invention encompasses a process for making compounds of Formula (I) useful in the treatment of inflammation and other cyclooxygenase-2 mediated diseases.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

- 1 -

TITLE OF THE INVENTION**PROCESS OF PREPARING PHENYL HETEROCYCLES USEFUL AS COX-2 INHIBITORS****5 BACKGROUND OF THE INVENTION**

This invention concerns a process for making certain anti-inflammatory compounds. In particular, the application concerns a process for making compounds of formula I as disclosed hereinafter, which compounds are potent cyclooxygenase-2 inhibitors.

10 Non-steroidal, anti inflammatory drugs exert most of their anti inflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase
15 had been characterized, this corresponding to cyclooxygenase-1 or the constitutive enzyme, as originally identified in bovine seminal vesicles. Recently the gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from chicken, murine and human sources. This enzyme is distinct from the
20 cyclooxygenase-1 which has now also been cloned, sequenced and characterized from sheep, murine and human sources. The second form of cyclooxygenase, cyclooxygenase-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both
25 physiological and pathological roles, we have concluded that the constitutive enzyme, cyclooxygenase-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the
30 inducible form, cyclooxygenase-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of cyclooxygenase-2 will have similar anti inflammatory, antipyretic and

- 2 -

analgesic properties to a conventional non-steroidal anti inflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects.


- 5 In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.

WO 94/ 15932 published July 21, 1994 discloses a multi-
10 step method of making bi-aryl furans via bi-aryl lactones, which method utilizes a keto-ester internal cyclization to the lactone. We have found that a significant amount of undesired by-products are produced by use of the disclosed process scheme, due to the external cyclization reactions which compete with the desired internal cyclization. While these by-
15 products can be removed by suitable separation and purification techniques, we have sought to identify alternative processes to obviate the difficulties. Use of compounds of Formula I as cyclooxygenase-2 inhibitors and methods of making them are disclosed in us 5,474,995, which is hereby incorporated by reference.

20

SUMMARY OF THE INVENTION

The invention encompasses a process for making compounds of Formula I useful in the treatment of inflammation and other cyclooxygenase-2 mediated diseases.




25

- 3 -

DETAILED DESCRIPTION OF THE INVENTION

In a first aspect, the invention encompasses a process for making compounds of Formula I useful in the treatment of inflammation and other cyclooxygenase-2 mediated diseases

5



R² is organic group such as mono- or di substituted phenyl wherein the substituent is selected from the group consisting of

10

- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃, and
- (7) C₁-6alkyl,

15


R³ and R^{3'} are each independently selected from hydrogen and C₁-4alkyl,

comprising:


20

- (b1) reacting in an inert solvent in the presence of Acetyl chloride and Aluminum chloride, thioanisole

- 4 -




to yield a compound of Formula 3



3

- For purposes of this specification, the inert solvent shall be defined to include ortho di-chlorobenzene, methylene chloride and chloroform. Ortho di-chlorobenzene is preferred. The molar ratio of Acetyl chloride to thioanisole is typically 0.9:1 to 1.5:1. Preferably excess Acetyl chloride (e.g. 1.2:1) is used. The mole ratio of Aluminum chloride to thioanisole is typically 0.9:1 to 1.5:1. Preferably excess Aluminum chloride (e.g. 1.2:1) is used.

(b2) reacting in an inert solvent in the presence of a phase transfer catalyst, and an oxidizing agent, compound of Formula 3 to yield a compound of Formula 4




4

- For purposes of this specification the phase transfer catalyst is defined to include tricapyrylmethyl ammonium chloride (ALIQAT) and tetrabutylammonium bromide. For purposes of this specification

- 5 -

the oxidizing agent is hydrogen peroxide. The oxidizing agent is optionally accompanied by sodium tungstate or other appropriate catalyst. The molar ratio of Formula 3 to oxidizing agent is typically 0.5:1 to 0.5 to 2. The amount of tungstate is typically 1 to 3 weight % of the amount of Formula 3. The amount of phase transfer catalyst used is typically 1 to 10 weight % of Formula 3.


(b3) reacting in aqueous acetic acid a compound of Formula 4 with Bromine to yield a compound of Formula 2



10


The molar ratio of bromine to Formula 4 is typically 0.9:1 to 1.1:1. Hydrogen bromide may be optionally added to initiate the reaction.

15 (b4) reacting in N,N-dimethylformamide a compound of Formula 2 with an acetic acid derivative of formula



in the presence of an inorganic base to produce a compound of Formula 5a

- 6 -



5a

5 For purposes of this specification, the inorganic base shall include Sodium hydroxide. The molar ratio of the phenyl acetic acid to compound of Formula 2 is typically 0.8:1 to 1:0.8. Preferably, excess phenyl acetic acid is used (e.g. 1.3:1). The molar ratio of inorganic base to Formula 2 is typically about 1:1. Preferably excess inorganic
10 base is used (about 1.1:1).


(b5) treating in a polar aprotic solvent the compound 5a with an organic base to yield a compound of Formula I.

15 For purposes of this specification, the polar aprotic solvent includes N,N-dimethylformamide, dimethylformamide, dimethylacetamide and N-methylpyrrolidone. The organic base includes diisopropylamine.

The resulting compound of Formula I can then be
20 crystallized from the product of step (b5), preferably at 40 to 60 °C.

- 7 -

Scheme 1




- 8 -

Friedel-Crafts Acylation

5 The synthesis of bromoketone 2 begins with the Friedel-Crafts reaction between thioanisole and acetyl chloride, to give 4-(methylthio)acetophenone 3 herein referred to as ketosulfide 3).

The Friedel-Crafts acylation of thioanisole (AlCl_3 - CH_3COCl , o-DCB) provided ketosulfide 3 selectively (>100:1 para:ortho). After aqueous workup the layers were separated and the o-DCB solution of ketosulfide 3 (97.5 % assay yield) was carried on
10 directly to the next step.



15 The Friedel-Crafts reaction involves pre-forming the AlCl_3 -acetyl chloride complex in o-DCB (about 1.2 equiv. of each reagent), followed by addition of thioanisole (1 equiv.). Both of these steps are exothermic and temperature control is desirable.


The use of o-DCB introduces a potential problem, namely
20 solvent acylation by the AlCl_3 -acetyl chloride complex, to give dichloroacetophenone. The formation of dichloroacetophenone is effectively minimized by conducting the acylation at -5 to 30°C preferably -5 to 25°C.

The reaction was usually complete within 30 min after the
25 thioanisole addition.

The reaction was quenched by slow transfer into water (exothermic). Applicants have found it desirable to maintain at 25°C or below.

30 Sulfide Oxidation

- 9 -



The Friedel-Crafts procedure provided a solution of ketosulfide 3 in o-dichlorobenzene which was to be oxidized directly.

- 5 The oxidation was carried out by adding aqueous hydrogen peroxide to a mixture consisting of the ketosulfide, o-DCB, water with sodium tungstate, and ALIQUAT 336 as the phase transfer catalyst. Ketosulfone 4 was isolated in 88% yield.

- 10 The oxidation was carried out using approximately 1-5 wt% sodium tungstate relative to the ketosulfide. Minimization of the catalyst charge was deemed desirable because preliminary results indicated that tungsten might be trapped in the isolated ketosulfone.


- 15 The reaction had an induction period of approximately 15 minutes and it is important to establish that the reaction is underway before charging the full amount of peroxide since initiation of the exothermic reaction at a late stage was potentially hazardous. Oxidation of the sulfide to sulfoxide and the sulfoxide to sulfone were carried out such that both occurred rapidly, thus avoiding a buildup of H₂O₂ after the first oxidation. This was achieved by addition of H₂O₂ to the
- 20 substrate-Na₂WO₄-ALIQUAT 336 mixture at elevated temperature. Once the oxidation is running, the exotherm maintained the temperature and sometimes cooling was necessary to maintain a reaction temperature of 45°-50°C. Heat was used during the 1-2 hour age to maintain the desired temperature range.

- 25 The method of product isolation is based on the solubility of the ketosulfone in o-DCB. As the oxidation neared completion, the ketosulfone precipitates from the reaction mixture. At the end of the reaction, excess H₂O₂ is destroyed by reaction with aqueous NaHSO₃, and the product is isolated by filtration of the three phase mixture. The
- 30 cake is washed with IPA to remove water and o-DCB and was dried, *in vacuo*, to give the product in 86-90% yield.

- 10 -

Bromination

The direct bromination of the ketosulfone **4** with bromine in HOAc, initiated with HBr and carried out at ambient temperature, gave a 93% conversion to 2-bromo-4-(methylsulfonyl)acetophenone **2** (herein on referred to as bromoketone **2**).



0.96-0.98 equivalents of bromine relative to ketosulfone results in a 93% conversion to bromoketone. Further addition of bromine tends to increase amounts of dibromoketone. The bromination reaction has an induction period ranging from 1-15 minutes on average. The reaction is exothermic and is preferably controlled to 25 to 24°C.

Addition of water (1 vol) to the slurry in HOAc followed by filtration provided an 87% yield of bromoketone **2**.


Brominations in acetic acid carried out at preferably 22-24°C at concentrations ranging from 3-10 ml acetic acid per gram of ketosulfone.

Coupling-Cyclization

Applicants have surprisingly found that the cyclization reaction was significantly faster in amide solvents (DMF, NMP, DMAC) than in ACN. Clean coupling reactions are achieved using amine bases, inorganic bases and AMBERLITE IRA 900. Inorganic bases are preferred for the coupling since the presence of amine hydrobromide salts (formed during coupling using amine bases) retarded the cyclization reaction. In the cyclization reaction, amine bases are surprisingly superior to inorganic bases such as carbonates and bicarbonates, in terms of product purity. The fastest and cleanest reaction was obtained using diisopropylamine.

- 11 -

The reaction sequence was carried out as follows. Sodium phenylacetate was generated *in situ* by reaction of phenylacetic acid with NaOH at 40°C. Addition of the bromoketone 2 effected rapid coupling to give 4-(methylsulfonyl)benzoylmethyl phenylacetate 5 (herein referred to as phenylacetic ester 5) which is then cyclized using diisopropylamine (DIPA) at 45°C. The product 1 was isolated by direct crystallization from the reaction mixture after addition of aqueous HCl and water.




10

The use of sodium phenylacetate in the coupling reaction with the bromoketone 2 is important due to the high solubility of NaBr (formed during the coupling reaction) in DMF. NaHCO₃-phenylacetic acid could be used but the coupling reaction was slow. Potassium phenylacetate (generated *in situ* from phenylacetic acid and KOH) or KHCO₃-phenylacetic acid should not be used as this results in precipitation of KBr, which is trapped in the product during the quench.

The coupling-cyclization sequence is preferably carried out using de-gassed DMF as solvent, since this was found to be advantageous in terms of product color. To avoid color impurities the solvent is degassed such as by nitrogen sparging.

The cyclization reaction is carried out using approximately 3 equiv. of DIA at 45°C. The coupling product (phenylacetic ester 5) is rapidly converted into the aldol intermediates 6 which are then converted into compound 1.

- 12 -



A cyclization reaction run at 40°C usually required 4.5 hours for complete conversion. Cyclization reactions using approximately 2 equiv of DIA or 2.5 equiv. of DIA at 45°C required approx. 4.25 h for complete reaction and provided Compound 1 in comparable yield and quality to that obtained using 3 equivalents of base.

The reaction was quenched by the addition of aq. 2N HCl (3.5 equiv. relative to bromoketone) at 20-30°C. This serves to neutralize the DIA and to effect product crystallization.

Final Product Recrystallization

Acetone and IPA has proven to be an excellent solvent combination for the recrystallization in terms of yield (90-92%), impurity rejection and color rejection. However, the moderate solubility of Compound 1 in acetone (approx. 25 mg/ml at 25°C) requires a large volume of solvent for batch dissolution and filtration. Subsequent concentration (vacuum distillation) increases processing time, and the need to separate and recycle acetone and IPA by distillation adds to cost and reduces efficiency.


A solution to the productivity issue requires a solvent in which Compound 1 is highly soluble. It has been surprisingly found that DMF-H₂O is an excellent solvent combination for the recrystallization in terms of yield (>95%), and impurity and color rejection. In general, however, use of DMF will result in a high level of residual solvent in the crystalized product. We have surprisingly found that when crystallization is carried out at 40 to 60 °C, we experience little entrapment of solvent (less than 0.2%). In comparison,

- 13 -

when the crystallization is carried out at room temperature, there is significant solvent entrapment (approximately 1 to 2%). Compound 1 has high solubility (135 mg/mL at 25°C) in DMF, which is well tolerated in the final product. Semi-pure Compound 1 is dissolved in
 5 DMF (6.5 mL/g, 50°C). The solution is filtered, to remove any extraneous matter, and water (8 mL/g) is slowly added (1 h) while maintaining the solution temperature at 50°C. The mixture is cooled to 25°C, aged 30 min and filtered. The cake is washed with DMF-H₂O (1:3), H₂O, and IPA, and then dried under vacuum (25°C) to give pure
 10 Compound 1 (98 % yield).

After the water addition the batch was cooled to 25°C and aged for 30 min prior to filtration. The batch is filtered and the cake was washed with DMF-H₂O (1:2), H₂O, and then IPA. The solid was then dried in a vacuum oven at 25°C to give the final product in 98%
 15 yield.

Synthesis of Ketosulphide 3



20

	MW	mol	equ	amount
Thioanisole	124.21	16.10	1.0	2 kg
Acetyl chloride	78.5	19.34	1.2	1.375 L
25 Aluminum chloride	133.3	19.34	1.2	2.58 kg
o-DCB				25 L
Water				31 L

A 50 L 4-neck round bottom flask equipped with a
 30 mechanical stirrer, N₂ line, and temperature probe was charged with o-DCB. The solution was cooled to -5°C and AlCl₃ was added.

Acetyl chloride was added, neat, *via* addition funnel, over a period of 10 min.

- 14 -

The resulting suspension was cooled to -5°C and thioanisole was added, *via* addition funnel, over 40 min.

Toward the end of the thioanisole addition a very heavy yellow slurry had formed. Efficient stirring was required (high torque mechanical stirrer). The slurry was aged at -2°C to +2°C for 60 min.


A 50 L 4-neck round bottom flask equipped with a mechanical stirrer and temperature probe, was charged with H₂O (15 L) which was then cooled to 10°C. The reaction mixture (temperature adjusted to +2°C so that the slurry is mobile enough to be transferred) was transferred slowly into the water (over 1 h), *via* wide bore teflon cannula, while stirring vigorously. The residual reaction mixture in the vessel was quenched with H₂O (2 L), which was then transferred to the quench mixture. During the quench the solution temperature was maintained between 10-22°C by controlling the rate of addition and by external cooling (ice-brine cooling bath).

The mixture was stirred vigorously at 10-25°C for 1.5 h.

The mixture was transferred into a 100 L extraction vessel and the layers were separated. The o-DCB layer (bottom layer) was charged into the extraction vessel, H₂O (7 L) was added and the mixture was stirred for 5 min at 25°C. The layers were separated and the o-DCB layer was analyzed by HPLC. A quantitative assay relative to a chromatographed standard indicated the formation of 2.61 kg of ketosulfide 3, a 97.5% assay yield.

The o-DCB solution of product was taken on directly to the next step.

Preparation of Ketosulfone 4



- 15 -

PROCEDURE

		MW	mol	equ	amount
5	Ketosulfide	166.23	0.59	1.0	98 g
	Na ₂ WO ₄ ·2H ₂ O	329.86	0.003	0.015	1.0 g
	Aliquat 336	404.17	0.012	0.02	5.0 g
	Aqueous 30% H ₂ O ₂	34.02	1.47	2.5	150 mL
	Aqueous 20% NaHSO ₃				152 mL
10	IPA				300 mL
	H ₂ O				300 mL
	Sulfuric acid (1M)				7 mL

15 A 1 L 3-neck round bottom flask equipped with a mechanical stirrer, temperature probe, addition funnel, and N₂ inlet was charged with sodium tungstate dihydrate (1.0g as a solution in 20 ml H₂O), sulfuric acid (1M, 4 mL), ketosulfide solution (1L of an o-DCB solution, 98g, 1 equiv.) and Aliquat 336.


20 The mixture was heated under a nitrogen atmosphere to 45°C. An addition funnel was charged with 150 ml aqueous 30% hydrogen peroxide and 15 ml was added to the ketosulfide-Na₂WO₄ mixture. The reaction was aged for 15 minutes and sampled.

25 The remainder of the hydrogen peroxide (135 ml) was added over 1 hour at a temperature of 45°C. The reaction was aged for 30 minutes and assayed.

The mixture was cooled to 18°C. The unreacted peroxide was quenched by the slow addition of aqueous 20 wt% sodium bisulfite solution. The temperature was maintained under 25 °C

30 The mixture was aged for 30 min at 22°C and was then filtered. The wet cake was washed once with H₂O (100 mL) and once with IPA (300 ml) and was then dried in vacuo at 40°C (nitrogen sweep) to give 104.7 g of ketosulfone (89.6% yield from thioanisole).

- 16 -

Synthesis of Brom ketone 2

5		MW	mmol	equ	amount
	Ketosulfone 4	198.23	0.522	1.0	103.5 g
	Bromine	159.82	0.506	0.97	80.89 g
	Aqueous 48% HBr				0.5 mL
10	Acetic acid				500 mL
	Water				700 mL
	HOAc:H ₂ O (1:1)				200 mL


15 A 2 L 3-neck round bottom flask equipped with a mechanical stirrer, temperature probe, addition funnel, and N₂ inlet was charged with glacial acetic acid, ketosulfone and aq. 48% HBr.

An addition funnel was charged with bromine. A 10% (8.1 g) charge of bromine gave an orange slurry which was aged 30 min at 25°C and was then sampled.

20 The bromination reaction has an induction period of 1-15 min after which bromine was rapidly consumed as it was added. The remainder of the bromine was added over 50 min at 20-25°C. The resulting pale yellow slurry was aged for 2 h at 22-25°C.

25 After ageing the mixture for 2-3 h the batch was filtered. The wet cake was washed once with 200 mL of 1:1 H₂O:HOAc and once with H₂O (200 mL). The cake was dried in vacuo at 40°C with a N₂ sweep to give 126.0 g of bromoketone (87%).

- 17 -

PREPARATION OF Compound 1

5		MW	mmol	equ	amount
	Bromoketone 2	277.13	30	1.0	8.31 g
	Phenylacetic acid	136.15	39	1.3	5.31 g
10	NaOH (50 wt%)		33	1.1	1.73 mL
	Diisopropylamine (DIA)		101.19	90	3.0 12.6 mL
	DMF				152.5 mL
	2 N HCl		105	3.5	52.5 mL
	H ₂ O				32 mL
15	IPA				27.5 mL

A 500 mL, baffled, 3-neck round bottom flask equipped with a mechanical stirrer, temperature probe, and nitrogen inlet was charged with phenylacetic acid and DMF (150 mL). The reaction vessel was flushed with N₂.

To the solution was added 50 wt% NaOH, resulting in a biphasic mixture. The resulting mixture was stirred vigorously at 4 °C for one hour.

The bromoketone 2 was added to the sodium phenylacetate solution.

The reaction flask was protected from the light due to the known light sensitivity of Compound 1. Diisopropylamine (DIA) was added *via* syringe (no exotherm), and the batch was aged at 45°C for 3.5 hours.

- 18 -

The reaction solution was cooled to 20-25°C, and 2N HCl was added over 1 h *via* addition funnel, maintaining the temperature between 20 and 30°C.

5 The product was further precipitated by addition of water (32 mL, *via* addition funnel) to the reaction slurry over 1 hour.

After ageing 1-2 hours at 25°C, the batch was filtered. The mother liquors were recycled to remove all of the product from the flask. The wet cake was washed once with 10 mL of 1:3 DMF:IPA and once with 20 mL IPA. The cake was dried by suction, to give 7.36 g of
10 semi-pure Compound 1 (78%).

RECRYSTALLIZATION OF Compound 1

	MW	mol	equ	amount
15				
	Semi-pure Compound 1	314	3.18	1.0 1 kg
	DMF			6.67 L
	H ₂ O			11.83 L
	isopropyl alcohol			2 L

20

A 12 L 4 neck round bottom flask equipped with a mechanical stirrer, temperature probe and nitrogen inlet was charged with semi-pure Compound 1 and DMF (5.5 L). The mixture was heated to 52°C over 20 min.

25

The solution was filtered into a 20 L 4-necked RB flask (equipped with a mechanical stirrer, nitrogen inlet, vacuum inlet and thermocouple) *via* an in line 1 micron filter. The vessel and line was flushed with 500 mL of DMF. The solution temperature was adjusted to 52°C and then water (7.5 L) was added *via* peristaltic pump, over 90
30 min.

During the water addition, the temperature was maintained between 49°C and 52°C. Crystals began to form after approximately 10% of the water was added.

The resulting slurry was allowed to cool to 25°C over 90
35 min.

- 19 -

The slurry was filtered, the cake was washed with DMF-H₂O (1:2, 2 L), H₂O (3 L), and then with 2 L IPA. The solid was dried for 12 h under vacuum at 25°C, to give 980 g (98%) of compound 1 as a pale yellow solid.

5


The following abbreviations have the indicated meanings:

Ac	=	acetyl
Aliquat	=	tricaprylmethyl ammonium chloride
DIA	=	diisopropylamine (also called DIPA)
DMAC	=	N,N-dimethylacetamide
DMAP	=	4-(dimethylamino)pyridine
DMF	=	N,N-dimethylformamide
HOAc	=	Acetic acid
IPA	=	isopropyl alcohol
NMP	=	1-methyl-2-pyrrolidinone
NSAID	=	non-steroidal anti-inflammatory drug
oDCB	=	ortho di-chloro benzene
THF	=	tetrahydrofuran

- 20 -

WHAT IS CLAIMED IS:

1. A method of making compounds of Formula I



wherein

R² is mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of


- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃, and
- (7) C₁-6alkyl,

R³ and R^{3'} are each independently selected from hydrogen and C₁-4alkyl,


comprising:

(b4) reacting in N,N-dimethylformamide a compound of Formula 2


- 21 -



with a phenyl acetic acid of formula



- 5 in the presence of an inorganic base to produce a compound of Formula 5a



10

(b5) treating in polar aprotic solvent the compound 5a with an organic base to yield a compound of Formula I.

2. A method according to Claim 1 wherein the inorganic
15 base is sodium hydroxide.

3. A method according to Claim 1 wherein the polar aprotic solvent is N,N-dimethylformamide.

- 22 -

4. A method according to Claim 1 wherein step (b5) is followed by crystallization at conducted at approximately 40 to 60 °C.


5. A method according to Claim 1 wherein
5 R² is mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of
 (1) hydrogen,
 (2) halo,
 (3) methoxy,
10 (4) methyl,
 R³ and R^{3'} are both hydrogen or are both methyl.

6. A method according to Claim 1 wherein
15 R² is mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of
 (1) hydrogen,
 (2) halo,
 R³ and R^{3'} are both hydrogen or are both methyl.

20 7. A method according to 1 wherein the compound of Formula I is
 (a) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone, or
 (b) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5*H*)-
25 furanone.


8. A method according to Claim 1 comprising
(b3) reacting in aqueous acetic acid a compound of Formula 4

- 23 -




4

with Bromine to yield a compound of Formula 2




2

5 (b4) reacting in N,N-dimethylformamide a compound of Formula 2 with a phenyl acetic acid of formula



in the presence of an inorganic base to produce a compound of Formula 5a




5a

- 24 -


(b5) treating in polar aprotic solvent the compound 5a with an organic base to yield a compound of Formula I.

5 9. A method according to Claim 8 wherein the phase transfer catalyst of step (b2) is tricapyrylmethyl ammonium chloride, sodium tungstate is added in step (b2) to catalyze the oxidation and hydrogen bromide is added in step (b3) to initiate the reaction.

10 10. A method according to Claim 9 comprising (b2) reacting in an inert solvent in the presence of a phase transfer catalyst, and an oxidizing agent, compound of Formula 3 to yield a compound of Formula 4




(b3) reacting in aqueous acetic acid a compound of Formula 4



15

with Bromine to yield a compound of Formula 2

- 25 -




(b4) reacting in N,N-dimethylformamide a compound of Formula 2 with a phenyl acetic acid of formula



5 in the presence of an inorganic base to produce a compound of Formula 5a

In a first aspect, the invention encompasses a process for making compounds of Formula I useful in the treatment of inflammation and other cyclooxygenase-2 mediated diseases

10



5a

15 (b5) treating in polar aprotic solvent the compound 5a with an organic base to yield a compound of Formula I.


11. A method according to Claim 10 wherein the inert solvent is ortho di-chlorobenzene, the phase transfer catalyst is

- 26 -

tricaprylmethyl ammonium chloride, and the oxidizing agent is hydrogen peroxide.

12. A process according to Claim 11 of making a compound of Formula I

5



R² is reaction stable organic group such as mono- or di substituted phenyl wherein the substituent is selected from the group consisting of

10

- (1) hydrogen,
- (2) halo,
- (3) C₁-6alkoxy,
- (4) C₁-6alkylthio,
- (5) CN,
- (6) CF₃, and
- (7) C₁-6alkyl,

15


R³ and R^{3'} are each independently selected from hydrogen and C₁-4alkyl,

comprising:


20

- (b1) reacting in an inert solvent in the presence of Acetyl chloride and Aluminum chloride, thioanisole

- 27 -




to yield a compound of Formula



3


5 (b2) reacting in an inert solvent in the presence of a phase transfer catalyst, and an oxidizing agent, compound of Formula 3 to yield a compound of Formula 4




4

10 (b3) reacting in aqueous acetic acid a compound of Formula 4 with Bromine to yield a compound of Formula 2

- 28 -




(b4) reacting in N,N-dimethylformamide a compound of
Formula 2
with an acetic acid derivative of formula



5

in the presence of an inorganic base to produce a compound of
Formula 5a



5a

10

(b5) treating in a polar aprotic solvent the compound 5a with an
organic base to yield a compound of Formula I.

INTERNATIONAL SEARCH REPORT

Intern at Application No

PCT/US 97/11466

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D307/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 18799 A (MERCK FROSST CANADA INC) 13 July 1995 see abstract; figures ---	1-12
A	WO 94 15932 A (SEARLE & CO ;MONSANTO CO (US); BERTENSHAW STEPHEN R (US); COLLINS) 21 July 1994 cited in the application see page 32; figure IV see page 59; example 13 see abstract ---	1-12
A	US 5 474 995 A (DUCHARME YVES ET AL) 12 December 1995 cited in the application see column 22 - column 23 -----	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

16 October 1997

Date of mailing of the international search report

27. 10. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9518799 A	13-07-95	US 5474995 A	12-12-95
		AU 1269495 A	01-08-95
		AU 1913297 A	14-08-97
		AU 6197096 A	31-10-96
		AU 6967494 A	17-01-95
		BG 100247 A	28-06-96
		BG 100350 A	31-12-96
		BR 9406979 A	05-03-96
		CA 2163888 A	05-01-95
		CA 2176973 A	25-12-94
		CA 2176974 A	25-12-94
		CA 2180651 A	13-07-95
		WO 9500501 A	05-01-95
		CN 1125944 A	03-07-96
		CN 1143365 A	19-02-97
		CZ 9503146 A	15-05-96
		EP 0705254 A	10-04-96
		EP 0739340 A	30-10-96
		EP 0754687 A	22-01-97
		FI 956119 A	19-12-95
		FI 962800 A	06-09-96
		HR 940373 A	31-12-96
		HU 74070 A	28-10-96
		HU 74986 A	28-03-97
		JP 9500372 T	14-01-97
		MX 9404749 A	31-01-95
		NO 955256 A	23-02-96
		NO 960393 A	09-07-96
		PL 312196 A	01-04-96
		SK 150295 A	08-01-97
		US 5536752 A	16-07-96
		US 5550142 A	27-08-96

WO 9415932 A	21-07-94	AU 6027694 A	15-08-94
		CA 2152792 A	21-07-94
		EP 0679157 A	02-11-95
		EP 0759432 A	26-02-97
		EP 0764644 A	26-03-97
		EP 0764645 A	26-03-97
		JP 8510718 T	12-11-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5474995 A	12-12-95	AU 1269495 A	01-08-95
		AU 1913297 A	14-08-97
		AU 6197096 A	31-10-96
		AU 6967494 A	17-01-95
		BG 100247 A	28-06-96
		BG 100350 A	31-12-96
		BR 9406979 A	05-03-96
		CA 2163888 A	05-01-95
		CA 2176973 A	25-12-94
		CA 2176974 A	25-12-94
		CA 2180651 A	13-07-95
		WO 9500501 A	05-01-95
		WO 9518799 A	13-07-95
		CN 1125944 A	03-07-96
		CN 1143365 A	19-02-97
		CZ 9503146 A	15-05-96
		EP 0705254 A	10-04-96
		EP 0739340 A	30-10-96
		EP 0754687 A	22-01-97
		FI 956119 A	19-12-95
		FI 962800 A	06-09-96
		HR 940373 A	31-12-96
		HU 74070 A	28-10-96
		HU 74986 A	28-03-97
		JP 9500372 T	14-01-97
		MX 9404749 A	31-01-95
		NO 955256 A	23-02-96
		NO 960393 A	09-07-96
		PL 312196 A	01-04-96
		SK 150295 A	08-01-97
		US 5536752 A	16-07-96
		US 5550142 A	27-08-96
		ZA 9404501 A	13-03-95